Danese S, Vermeire S, Zhou W, Pangan AL, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022 May 26. pii: S0140-6736(22)00581.
PMID: 35644166